BLAINJECTIONINJECTABLE
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
DYSPORT (botulinum toxin type a) by Ipsen is acetylcholine release inhibitors [moa]. Approved for muscle spasticity, cervical dystonia, overactive bladder and 6 more indications. First approved in 2009.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYSPORT is a botulinum toxin type A injection approved for cervical dystonia in adults and spasticity in patients 2 years and older. It works by inhibiting acetylcholine release at the neuromuscular junction, reducing muscle contractions. The product is administered via intramuscular injection.
$3MPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $3M on 1,579 claims, the commercial team is likely in defensive mode focused on retention and off-label optimization.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications (9)
Worked on DYSPORT at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.